Products for Research Use Only

VMD-928

CAT: 0804-HY-171450-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-171450-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma[1][2].
CAS Number
1802770-18-8
UNSPSC
12352005
Target
Trk Receptor
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(C1=CC=C(NC(C=C(N2CCN(C3CCCCC3)CC2)C(N)=C4C(C5=C6C=CC=C5)=O)=C4C6=O)C=C1)O
Molecular Formula
C31H32N4O4
Molecular Weight
524.61
References & Citations
[1]Di Donato M, et al. The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. Cell Biosci. 2023 Mar 20;13 (1) :60.|[2]Chung V, et al. First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma[J]. 2019.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1